Stock listing
BOATS:SRZN Surrozen, Inc. Stock
US listing (BOATS) of Surrozen, Inc. · home listing NASDAQ:SRZN
Follow Surrozen, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SRZN
$28.46 USD -3.28 (-10.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SRZN
- Day range
- $28.25 – $30.34 USDNov 20, 2026
- Volume
- 148,849 sharesNov 20, 2026
- Market cap
- $542.5M USDAt the close on Nov 20, 2026 · price × 19.06M shares outstanding
- 52-week range
- $12.79 – $37.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15.45M USDMedian day 219,973 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SRZN · Home | $28.46 USD | -3.28 (-10.3%) | 148,849 | $29.92 | $30.34 | $28.25 | $31.74 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SRZN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $28.46 | -3.28 | -10.3% | $29.92 | $30.34 | $28.25 | 148,849 | |
| $31.74 | +1.76 | +5.9% | $29.75 | $32.73 | $29.75 | 312,926 | |
| $29.98 | -2.34 | -7.2% | $31.86 | $31.88 | $29.30 | 218,218 | |
| $32.32 | +0.71 | +2.2% | $31.34 | $33.09 | $30.78 | 274,400 | |
| $31.61 | -0.06 | -0.2% | $32.34 | $32.87 | $30.40 | 106,708 | |
| $31.67 | -0.21 | -0.7% | $32.31 | $32.45 | $30.53 | 134,041 | |
| $31.88 | -0.76 | -2.3% | $33.43 | $33.74 | $31.69 | 157,137 | |
| $32.64 | +0.64 | +2.0% | $32.63 | $33.62 | $31.23 | 197,895 | |
| $32.00 | +1.00 | +3.2% | $31.32 | $33.50 | $31.09 | 120,849 | |
| $31.00 | +2.00 | +6.9% | $29.02 | $31.23 | $29.00 | 140,726 | |
| $29.00 | -2.65 | -8.4% | $31.36 | $31.36 | $28.68 | 219,973 | |
| $31.65 | +1.53 | +5.1% | $30.78 | $32.80 | $30.39 | 231,054 | |
| $30.12 | +1.10 | +3.8% | $29.52 | $30.24 | $28.53 | 117,728 | |
| $29.02 | -0.02 | -0.1% | $29.16 | $30.30 | $27.96 | 159,249 | |
| $29.04 | -0.42 | -1.4% | $29.32 | $29.51 | $27.72 | 231,860 | |
| $29.46 | -0.89 | -2.9% | $30.41 | $31.61 | $29.10 | 254,712 | |
| $30.35 | +0.82 | +2.8% | $29.45 | $30.53 | $29.45 | 142,656 | |
| $29.53 | +2.25 | +8.2% | $27.38 | $30.34 | $27.28 | 431,554 | |
| $27.28 | +1.80 | +7.1% | $25.23 | $27.75 | $24.97 | 511,122 | |
| $25.48 | -0.27 | -1.0% | $25.11 | $26.79 | $24.56 | 1,554,600 | |
| $25.75 | +0.43 | +1.7% | $25.32 | $27.68 | $24.85 | 137,000 | |
| $25.32 | +0.18 | +0.7% | $25.78 | $26.09 | $24.98 | 118,800 | |
| $25.14 | +1.30 | +5.5% | $23.74 | $25.45 | $23.38 | 323,900 | |
| $23.84 | +0.40 | +1.7% | $23.51 | $24.48 | $23.25 | 295,900 | |
| $23.44 | -1.63 | -6.5% | $25.09 | $25.09 | $23.25 | 269,000 | |
| $25.07 | +1.32 | +5.6% | $23.73 | $25.32 | $23.31 | 363,800 | |
| $23.75 | +0.24 | +1.0% | $23.40 | $24.54 | $22.67 | 631,500 | |
| $23.51 | -1.25 | -5.0% | $24.04 | $24.37 | $21.85 | 868,700 | |
| $24.76 | -4.93 | -16.6% | $28.70 | $30.08 | $22.82 | 1,528,600 | |
| $29.69 | +1.72 | +6.1% | $27.86 | $30.97 | $27.53 | 781,300 | |
| $27.97 | +2.825 | +11.2% | $25.00 | $28.85 | $23.54 | 682,200 | |
| $25.15 | -1.225 | -4.6% | $25.81 | $26.21 | $25.08 | 374,200 | |
| $26.37 | -2.76 | -9.5% | $29.26 | $29.26 | $26.18 | 603,800 | |
| $29.13 | -0.19 | -0.6% | $29.32 | $29.70 | $26.97 | 439,200 | |
| $29.32 | -0.68 | -2.3% | $30.57 | $30.68 | $28.93 | 646,000 | |
| $30.00 | -2.18 | -6.8% | $31.60 | $32.00 | $29.72 | 438,400 | |
| $32.18 | +0.20 | +0.6% | $32.16 | $33.38 | $30.98 | 1,656,600 | |
| $31.98 | +2.34 | +7.9% | $29.83 | $32.55 | $29.50 | 558,000 | |
| $29.64 | +0.10 | +0.3% | $29.71 | $30.39 | $29.01 | 409,700 | |
| $29.54 | -4.14 | -12.3% | $34.72 | $37.83 | $28.55 | 1,928,700 | |
| $33.68 | +17.52 | +108.4% | $30.56 | $35.86 | $29.10 | 11,527,000 | |
| $16.16 | -1.44 | -8.2% | $17.54 | $17.54 | $16.14 | 115,500 | |
| $17.60 | +1.07 | +6.5% | $16.78 | $17.60 | $16.56 | 89,800 | |
| $16.53 | -0.02 | -0.1% | $16.74 | $17.45 | $16.44 | 129,000 | |
| $16.55 | -0.39 | -2.3% | $16.97 | $17.68 | $16.43 | 190,200 | |
| $16.94 | +0.01 | +0.1% | $17.27 | $17.48 | $16.44 | 268,500 | |
| $16.93 | -0.84 | -4.7% | $17.84 | $17.86 | $16.78 | 116,700 | |
| $17.77 | -0.07 | -0.4% | $17.81 | $18.34 | $17.15 | 151,900 | |
| $17.84 | -1.16 | -6.1% | $19.03 | $19.29 | $17.61 | 198,200 | |
| $19.00 | -0.45 | -2.3% | $19.68 | $19.72 | $18.71 | 145,300 | |
| $19.45 | -0.58 | -2.9% | $19.95 | $20.15 | $19.00 | 277,800 | |
| $20.03 | -0.65 | -3.1% | $20.52 | $20.52 | $18.40 | 201,900 | |
| $20.68 | -2.08 | -9.1% | $22.57 | $23.18 | $20.63 | 202,300 | |
| $22.76 | +0.22 | +1.0% | $22.34 | $22.90 | $21.54 | 150,200 | |
| $22.54 | -0.06 | -0.3% | $22.92 | $22.99 | $22.24 | 200,900 | |
| $22.60 | +0.40 | +1.8% | $22.32 | $23.01 | $21.90 | 116,900 | |
| $22.20 | +0.18 | +0.8% | $21.72 | $22.48 | $21.65 | 124,600 | |
| $22.02 | -0.40 | -1.8% | $22.28 | $22.62 | $21.45 | 266,700 | |
| $22.42 | -1.59 | -6.6% | $23.75 | $23.75 | $22.08 | 239,400 | |
| $24.01 | +0.30 | +1.3% | $23.69 | $24.87 | $23.03 | 340,700 | |
| $23.71 | +0.35 | +1.5% | $23.52 | $24.16 | $23.19 | 128,800 | |
| $23.36 | -0.61 | -2.5% | $23.97 | $25.01 | $23.29 | 218,967 | |
| $23.97 | -0.02 | -0.1% | $23.81 | $24.33 | $22.80 | 163,644 | |
| $23.99 | +0.49 | +2.1% | $23.73 | $25.01 | $23.49 | 149,700 | |
| $23.50 | -0.51 | -2.1% | $24.46 | $24.46 | $23.09 | 135,300 |
Splits
1 split · NASDAQ:SRZN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation |
- Ticker
- BOATS:SRZN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 21 slides
Latest news
Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
Nov 13, 2026
Closed $31.61 (-0.2%) on Nov 13, 2026
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 9, 2026
Closed $32.64 (+2.0%) on Nov 10, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
Nov 6, 2026
Closed $32.00 (+3.2%) on Nov 9, 2026
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Oct 20, 2026
Closed $25.32 (+0.7%) on Oct 21, 2026
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Oct 2, 2026
Closed $29.32 (-2.3%) on Oct 2, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
Aug 6, 2026
Closed $25.62 (+18.4%) on Aug 7, 2026
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $25.62 (+18.4%) on Aug 7, 2026
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Closed $30.75 (-9.9%) on May 7, 2026
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 23, 2026
Closed $25.24 (+0.4%) on Mar 23, 2026
Surrozen to Present at Upcoming Healthcare Investor Conferences
Nov 25, 2025
Closed $16.45 (+2.7%) on Nov 26, 2025
Surrozen, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 50 in all · newest Nov 13, 2026 · oldest 2021
- Calls
- 1 call with a replay · 1 with a transcript · latest Mar 23, 2023
- Decks
- 7 decks · latest November 2026
Where Surrozen, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SRZN · Home listing | NASDAQ | United States | USD |
| BOATS:SRZN · This page | BOATS | United States | USD |
Valuation
EV/sales 42.5× against a median of 30.2×: 5th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $448.0M USD
- P/E
- Loss
- EV/sales
- 42.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 5.0%
- Operating margin
- −485.4%
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.64
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.4M | 14.6× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.7M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Median of the others | US$550.2M | US$255.1M | 14.6× | 30.2× | 22.9× | 1.7× | −90.3% | 0.0× | 1.43 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 53.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -18.78 · 1 analyst
- Revenue, year to Dec 2026
- 10M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Craig Parker | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Chris Chai | Chair |
| David J. Woodhouse | Chairman of the Board |
| Tim Kutzkey | Chair |
| Craig Parker | Chief Executive Officer |
| Mace Rothenberg | Independent Board Member |
| Mary Haak-Frendscho | Independent Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Surrozen (NASDAQ:SRZN) Q4 2022 Earnings Call | Thu, Mar 23, 2023 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | +2.0% |
| Q2 2026 | Aug 14, 2026 | +0.2% |
| Q1 2026 | May 6, 2026 · After close | −9.9% |
| Q4 2025 | Mar 24, 2026 | +3.6% |
| Q3 2025 | Nov 7, 2025 · After close | −3.3% |
| Q2 2025 | Aug 8, 2025 · After close | +4.5% |
| Q1 2025 | May 9, 2025 · After close | −4.2% |
| Q4 2024 | Mar 31, 2025 | +1.0% |
| Q3 2024 | Nov 6, 2024 · Before open | −5.1% |
| Q2 2024 | Aug 12, 2024 · After close | −10.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +0.3% |
| Q4 2023 | Mar 19, 2024 · After close | +8.0% |
| Q3 2023 | Nov 8, 2023 · After close | −21.2% |
| Q2 2023 | Aug 9, 2023 · After close | −32.2% |
| Q1 2023 | May 10, 2023 · After close | −9.5% |
| Q4 2022 | Mar 22, 2023 · After close | −22.6% |
| Q3 2022 | Nov 14, 2022 · After close | −30.2% |
| Q2 2022 | Aug 11, 2022 · After close | −3.3% |
| Q1 2022 | May 11, 2022 · After close | +1.6% |
| Q4 2021 | Mar 24, 2022 · Before open | −6.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 21 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 21 slides | October 2026 |
| Investor Presentation (March 2026) | Investor deck | 21 slides | March 2026 |
| Investor Presentation (January 2026) | Investor deck | 21 slides | January 2026 |
| Investor Presentation (April 2024) | Investor deck | 24 slides | Apr 1, 2024 |
| Investor Presentation (August 2021) | Investor deck | 36 slides | Aug 12, 2021 |
| SPAC Merger (April 2021) | SPAC merger | 31 slides | Apr 15, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$60M · US$31.67 a share · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead) Buyers: Access Biotechnology; Boxer Capital Management; Perceptive Advisors; RTW Investments; Venrock Healthcare Capital Partners | Nov 13, 2026 |
| At-the-market programme of common stock Closed: US$29.8M raised Use of proceeds: Strengthening the balance sheet and supporting the expansion of the DUET Phase 2a study | Nov 9, 2026 |
| Warrant exercise of common stock warrants Closed: US$1.1M raised | Nov 9, 2026 |
| Private placement of common stock, pre-funded warrants and Series E common stock warrants Closed: US$95.1M raised · Warrants at US$11.54 Use of proceeds: Strengthen balance sheet and fund cash runway into 2029, including the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143 | Oct 20, 2026 |
| Private placement of units of common stock (or pre-funded warrants) and accompanying common stock warrants Tranche closed: US$76.4M raised · US$11.6 a unit · one half of a common stock warrant per unit · Guggenheim Securities, LLC Dealers: Guggenheim Securities, LLC (lead) Buyers: Venrock Healthcare Capital Partners (led the financing); The Column Group; Access Biotechnology; RA Capital Management; Vivo Capital; Spruce Street Capital; 5AM Ventures; Kalehua Capital; Samsara BioCapital; Acuta Capital Partners; StemPoint Capital; Braidwell LP Use of proceeds: Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies | Mar 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Consonance-HFW Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Nov 18, 2020.
- Price
- US$10.00 a unit
- Units offered
- 8,000,000 units
- Offering size
- US$80 million
- Underwriters' option
- Up to 1,200,000 more units
- Listing
- CHFW.U on NYSE American
- Underwriter
- J.P. Morgan
- Units delivered
- On or about Nov 23, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 18, 2020 |
| Filed publicly | Oct 9, 2020 |
| Amended 5 times | Newest Nov 12, 2020 |
| Shares registered with an exchange | Oct 19, 2020 |
| Declared effective by the SEC | Nov 18, 2020 |
| Final prospectus, with the price | Nov 19, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 19, 2020 |
| EFFECT · Notice that a registration is effective | Nov 18, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| S-1/A · Registration statement, amended | Nov 12, 2020 |
| CERT · Exchange's certificate of listing | Nov 10, 2020 |
| S-1/A · Registration statement, amended | Nov 6, 2020 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Nov 4, 2020 |
| CORRESP · Letter to the SEC | Oct 27, 2020 |
| S-1/A · Registration statement, amended | Oct 27, 2020 |
All 25 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 27, 2020 |
| CORRESP · Letter to the SEC | Oct 27, 2020 |
| UPLOAD · Letter from the SEC | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 26, 2020 |
| CERT · Exchange's certificate of listing | Oct 26, 2020 |
| S-1/A · Registration statement, amended | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 19, 2020 |
| S-1/A · Registration statement, amended | Oct 13, 2020 |
| S-1 · Registration statement | Oct 9, 2020 |
| DRS · Draft registration statement | Sep 18, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 19, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.48M | 10.7M | 0 | 12.5M | 0 | 0 | |
| Cost of revenue | 537.0K | 1.44M | 27.2M | 3.27M | 3.30M | 2.93M | |
| Gross profit | 2.94M | 10.7M | -27.2M | 12.5M | -3.30M | -2.93M | |
| Research and development | 29.4M | 21.1M | 27.2M | 37.0M | 40.2M | 25.7M | 19.6M |
| Selling, general and administrative | 16.2M | 15.1M | 15.8M | 19.8M | 14.2M | 7.12M | 5.50M |
| Operating income | -42.1M | -25.5M | -45.8M | -44.3M | -54.4M | -32.8M | -25.1M |
| Depreciation and amortization | 537.0K | 1.44M | 1.91M | 1.96M | 2.07M | 1.94M | 2.28M |
| EBITDA | -41.6M | -24.1M | -43.9M | -42.4M | -52.3M | -30.9M | -22.8M |
| Interest expense | 1.96M | 2.07M | 91.0K | 0 | |||
| Income before tax | -242.0M | -63.6M | -43.0M | -36.0M | -54.6M | -32.7M | -24.4M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -242.0M | -63.6M | -43.0M | -36.0M | -54.6M | -32.7M | -24.4M |
| Earnings per share, basic | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 | -1.79 | -61.94 |
| Earnings per share, diluted | -32.37 | -21.67 | -21.33 | -15.56 | -2.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 89.2M | 34.6M | 36.0M | 24.7M | 33.1M | 35.0M | 29.1M |
| Short-term investments | 0 | 51.1M | 68.8M | 14.2M | |||
| Receivables | 0 | 2.04M | 2.15M | 1.98M | 0 | ||
| Inventory | 1 | ||||||
| Current assets | 91.6M | 38.9M | 41.1M | 81.3M | 105.2M | 50.2M | 29.4M |
| Property, plant and equipment | 433.0K | 562.0K | 1.97M | 3.63M | 4.79M | 5.84M | 12.6M |
| Total assets | 98.7M | 48.5M | 46.1M | 89.4M | 137.2M | 62.1M | 42.5M |
| Accounts payable | 728.0K | 306.0K | 525.0K | 658.0K | 2.72M | 1.78M | 972.0K |
| Current liabilities | 9.93M | 7.32M | 7.15M | 9.73M | 13.6M | 7.28M | 3.90M |
| Total debt | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M | 9.60M | 10.7M |
| Total liabilities | 286.5M | 69.8M | 8.14M | 13.4M | 27.5M | 14.8M | 13.1M |
| Shareholders' equity | -187.8M | -21.4M | 37.9M | 76.0M | 109.7M | 47.3M | 29.4M |
| Shares outstanding | 9.78M | 3.26M | 2.06M | 2.01M | 35.0M | 18.3M | 393.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -30.2M | -17.6M | -40.4M | -44.1M | -48.8M | -29.1M | -21.1M |
| Capital spending | -128.0K | -26.0K | -398.0K | -728.0K | -1.27M | -874.0K | -1.56M |
| Free cash flow | -30.4M | -17.7M | -40.8M | -44.9M | -50.1M | -30.0M | -22.6M |
| Cash from investing | -128.0K | -26.0K | 51.7M | 38.3M | -77.7M | -15.1M | -1.56M |
| Cash from financing | 85.1M | 16.2M | 276.0K | -2.56M | 124.6M | 50.1M | 28.9M |
| Dividends paid | -48.4M | ||||||
| Share buybacks | 198.0K | 94.0K | 0 | -2.61M | 0 | -1.00K | -13.0K |
| Change in cash | 54.7M | -1.48M | 11.6M | -8.40M | -1.89M | 5.88M | 29.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 18, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| FWP · Free writing prospectus | Nov 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 11, 2026 | Big-stake notice | SEC |
| 25-NSE | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 8-K · Current report | May 14, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 1, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 31, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 30, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 20, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2025 | Results | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| 8-K · Current report | Aug 29, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 29, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 2, 2025 | Other filings | SEC |
| 424B5 · Prospectus | May 1, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Apr 24, 2025 | Offer document | SEC |
| S-3 · Registration statement | Apr 23, 2025 | Offer document | SEC |
| D | Apr 8, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 2, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 2, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 2, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 31, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2025 | Material contract | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 1, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 2, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
This page holds 200 of 513 filings. Open Filings
Cap table
Built by 6ix from Surrozen, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 19,061,662
- Fully diluted
- 22,078,909
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 19,061,662 | Nov 5, 2026 |
| Warrants | 3,017,247 | Mar 26, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$11.54 · expiry not stated |
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 19,061,662 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eric H. Bjerkholt Other companies: Mirum Pharmaceuticals, Inc. (CHIEF FINANCIAL OFFICER · Since at least Aug 11, 2025); Cerus Corporation (Director · Since at least Jun 3, 2025); Metagenomi Therapeutics, Inc. (Director · Since at least Jan 16, 2025) | Director · Since at least May 14, 2025 |
| Christopher Haqq Other companies: Elicio Therapeutics, Inc. (Executive Vice President, Head of Research and Development and Chief Medical Officer · Since at least Jun 1, 2023); Atara Biotherapeutics, Inc. (EVP, R&D & Chief Scientific Of · Oct 15, 2014 – Feb 15, 2019 · Past) | Director · Nov 18, 2020 – Nov 18, 2020 · Past |
| Anna Berkenblit Other companies: ImmunoGen Inc (SVP & CHIEF MEDICAL OFFICER · May 20, 2022 – Jun 30, 2023 · Past) | Director · Since at least Jun 7, 2022 |
| Christopher Y Chai Other companies: Principia Biopharma Inc (Chief Financial Officer · Sep 13, 2018 – Sep 28, 2020 · Past) | Director · Since at least Aug 11, 2021 |
| David J. Woodhouse Other companies: NGM Biopharmaceuticals Inc (Chief Executive Officer, Director · Apr 3, 2019 – Apr 5, 2024 · Past) | Chairman of the Board · Since at least Aug 11, 2021 |
| Geertrui Vanhove Other companies: INSYS Therapeutics Inc (Director · Apr 2, 2018 – Apr 2, 2018 · Past) | Chief Medical Officer · Aug 11, 2021 – Dec 15, 2022 · Past |
| Mace Rothenberg Other companies: Tango Therapeutics, Inc. (Director · Since at least Aug 10, 2021) | Director · Since at least Aug 11, 2021 |
| Andrew Pedrum Maleki | Chief Financial Officer · Since at least Nov 12, 2025 |
| Benny Soffer | Director · Nov 18, 2020 – Dec 1, 2020 · Past |
| Charles O Williams | Chief Operating Officer · Since at least Aug 11, 2021 |
All 19 people
| Person | Seat |
|---|---|
| Chris Chai | Chair · Since at least Nov 4, 2026 |
| Craig Parker | Chief Executive Officer, Director · Since at least May 1, 2026 |
| Kevin Harold Livingston | Chief Financial Officer · Nov 18, 2020 – Dec 1, 2020 · Past |
| Life Sciences Consonance | Director · Nov 18, 2020 – Dec 1, 2020 · Past |
| Mary Haak-Frendscho | Independent Board Member · Since at least Nov 4, 2026 |
| Tim Kutzkey | Director · Since at least Aug 11, 2021 |
| Tim Kutzkey | Chair · Since at least Mar 24, 2025 |
| Wen-Chen Yeh | Chief Scientific Officer · Aug 11, 2021 – Jun 15, 2023 · Past |
| Yang Li | Exec. Vice President, Research · Since at least Aug 17, 2023 |
Log in to ask 6ix AI your own questions about Surrozen, Inc.